There have been no well-controlled clinical studies of the use of North American Coral Snake Antivenin (Equine) in patients experiencing envenomation by the Eastern Coral Snake, however a retrospective analysis3 has been published of 387 coral snake exposures treated in a healthcare facility in Florida between 1998 and 2010, including 252 patients who were treated with North American Coral Snake Antivenin (Equine). Patients were managed according to different treatment strategies: (a) asymptomatic at ED arrival and treated empirically (n=134); (b) asymptomatic at ED arrival, but treatment withheld until symptoms appeared (n=106; 6 of the 106 received North American Coral Snake Antivenin (Equine) at some point; the remainder were never treated); (c) symptomatic at ED arrival and treated with North American Coral Snake Antivenin (Equine) (n=112); and (d) symptomatic at ED arrival but not treated with North American Coral Snake Antivenin (Equine) (n=35). The average number of vials administered to treated patients was 3.75 (range 1 – 20 vials); the 17 patients who received repeat treatment were administered 8.3 vials, on average. There was no reported usage of foreign antivenom or acetylcholinesterase inhibitors in this case series. The 387 patients were assessed for clinical outcomes, as shown in Table 1. Outcomes codes range from full recovery with no residual effects ("No Effect") to less than full recovery with significant residual effects ("Major"). Empiric treatment of asymptomatic patients resulted in more 'moderate' and 'major' outcomes compared to withholding treatment until symptoms appeared (p<.001), however, the patients were not randomized and selection biases could have affected this result.
| Treatment Strategy | Empiric (N = 134) | Withhold (N = 106) | Symptomatic with AV (N = 112) | Symptomatic without AV (N = 35) |
|---|---|---|---|---|
| ADR, adverse drug reaction; AV, antivenom; Avg, average; LOS, length of stay; ICU, intensive care unit. | ||||
| ||||
| Primary outcome | ||||
| Endotracheal intubation (%) | 3 (2.2) | 1 (0.94) | 7 (6.25) | 0 (0) |
| Secondary outcomes | ||||
| Days intubated Avg. (SD) | 5.67 (2.89) | 24 (N/A) | 8 (6.22) | 0 (0) |
| ICU admission (%)* | 97 (72.39) | 49 (46.23) | 90 (80.36) | 9 (25.71) |
| ICU LOS Avg.(SD) | 1.5 (1.18) | 1.73 (3.28) | 2.25 (3.35) | 1.3 (0.5) |
| Total LOS Avg.(SD) | 1.58 (1.56) | 1.17 (2.94) | 2.47 (3.68) | 0.94 (0.85) |
| Antivenom ADR (%)* | 26 (19.4) | 0 (0) | 20 (17.86) | 0 (0) |
| Outcome code %* | ||||
| No Effect | 4.76 | 29.29 | 0 | 0 |
| Minor | 71.43 | 56.57 | 34.23 | 63.64 |
| Moderate | 20.63 | 13.13 | 54.05 | 36.36 |
| Major | 3.17 | 1.01 | 11.71 | 0 |
Adverse reactions associated with North American Coral Snake Antivenin (Equine) administration were documented in 46 (18.25%) cases. The most common adverse reactions were hives, rash and/or welts (12%); itching (9%); shortness of breath (8%); hypotension (2%) and angioedema (1%). Antihistamines were administered to 46 patients, corticosteroids to 40, and epinephrine to 10 cases to treat these adverse reactions.
There have been no well-controlled clinical studies of the use of North American Coral Snake Antivenin (Equine) in patients experiencing envenomation by the Eastern Coral Snake, however a retrospective analysis3 has been published of 387 coral snake exposures treated in a healthcare facility in Florida between 1998 and 2010, including 252 patients who were treated with North American Coral Snake Antivenin (Equine). Patients were managed according to different treatment strategies: (a) asymptomatic at ED arrival and treated empirically (n=134); (b) asymptomatic at ED arrival, but treatment withheld until symptoms appeared (n=106; 6 of the 106 received North American Coral Snake Antivenin (Equine) at some point; the remainder were never treated); (c) symptomatic at ED arrival and treated with North American Coral Snake Antivenin (Equine) (n=112); and (d) symptomatic at ED arrival but not treated with North American Coral Snake Antivenin (Equine) (n=35). The average number of vials administered to treated patients was 3.75 (range 1 – 20 vials); the 17 patients who received repeat treatment were administered 8.3 vials, on average. There was no reported usage of foreign antivenom or acetylcholinesterase inhibitors in this case series. The 387 patients were assessed for clinical outcomes, as shown in Table 1. Outcomes codes range from full recovery with no residual effects ("No Effect") to less than full recovery with significant residual effects ("Major"). Empiric treatment of asymptomatic patients resulted in more 'moderate' and 'major' outcomes compared to withholding treatment until symptoms appeared (p<.001), however, the patients were not randomized and selection biases could have affected this result.
| Treatment Strategy | Empiric (N = 134) | Withhold (N = 106) | Symptomatic with AV (N = 112) | Symptomatic without AV (N = 35) |
|---|---|---|---|---|
| ADR, adverse drug reaction; AV, antivenom; Avg, average; LOS, length of stay; ICU, intensive care unit. | ||||
| ||||
| Primary outcome | ||||
| Endotracheal intubation (%) | 3 (2.2) | 1 (0.94) | 7 (6.25) | 0 (0) |
| Secondary outcomes | ||||
| Days intubated Avg. (SD) | 5.67 (2.89) | 24 (N/A) | 8 (6.22) | 0 (0) |
| ICU admission (%)* | 97 (72.39) | 49 (46.23) | 90 (80.36) | 9 (25.71) |
| ICU LOS Avg.(SD) | 1.5 (1.18) | 1.73 (3.28) | 2.25 (3.35) | 1.3 (0.5) |
| Total LOS Avg.(SD) | 1.58 (1.56) | 1.17 (2.94) | 2.47 (3.68) | 0.94 (0.85) |
| Antivenom ADR (%)* | 26 (19.4) | 0 (0) | 20 (17.86) | 0 (0) |
| Outcome code %* | ||||
| No Effect | 4.76 | 29.29 | 0 | 0 |
| Minor | 71.43 | 56.57 | 34.23 | 63.64 |
| Moderate | 20.63 | 13.13 | 54.05 | 36.36 |
| Major | 3.17 | 1.01 | 11.71 | 0 |
Adverse reactions associated with North American Coral Snake Antivenin (Equine) administration were documented in 46 (18.25%) cases. The most common adverse reactions were hives, rash and/or welts (12%); itching (9%); shortness of breath (8%); hypotension (2%) and angioedema (1%). Antihistamines were administered to 46 patients, corticosteroids to 40, and epinephrine to 10 cases to treat these adverse reactions.
There have been no well-controlled clinical studies of the use of North American Coral Snake Antivenin (Equine) in patients experiencing envenomation by the Eastern Coral Snake, however a retrospective analysis3 has been published of 387 coral snake exposures treated in a healthcare facility in Florida between 1998 and 2010, including 252 patients who were treated with North American Coral Snake Antivenin (Equine). Patients were managed according to different treatment strategies: (a) asymptomatic at ED arrival and treated empirically (n=134); (b) asymptomatic at ED arrival, but treatment withheld until symptoms appeared (n=106; 6 of the 106 received North American Coral Snake Antivenin (Equine) at some point; the remainder were never treated); (c) symptomatic at ED arrival and treated with North American Coral Snake Antivenin (Equine) (n=112); and (d) symptomatic at ED arrival but not treated with North American Coral Snake Antivenin (Equine) (n=35). The average number of vials administered to treated patients was 3.75 (range 1 – 20 vials); the 17 patients who received repeat treatment were administered 8.3 vials, on average. There was no reported usage of foreign antivenom or acetylcholinesterase inhibitors in this case series. The 387 patients were assessed for clinical outcomes, as shown in Table 1. Outcomes codes range from full recovery with no residual effects ("No Effect") to less than full recovery with significant residual effects ("Major"). Empiric treatment of asymptomatic patients resulted in more 'moderate' and 'major' outcomes compared to withholding treatment until symptoms appeared (p<.001), however, the patients were not randomized and selection biases could have affected this result.
| Treatment Strategy | Empiric (N = 134) | Withhold (N = 106) | Symptomatic with AV (N = 112) | Symptomatic without AV (N = 35) |
|---|---|---|---|---|
| ADR, adverse drug reaction; AV, antivenom; Avg, average; LOS, length of stay; ICU, intensive care unit. | ||||
| ||||
| Primary outcome | ||||
| Endotracheal intubation (%) | 3 (2.2) | 1 (0.94) | 7 (6.25) | 0 (0) |
| Secondary outcomes | ||||
| Days intubated Avg. (SD) | 5.67 (2.89) | 24 (N/A) | 8 (6.22) | 0 (0) |
| ICU admission (%)* | 97 (72.39) | 49 (46.23) | 90 (80.36) | 9 (25.71) |
| ICU LOS Avg.(SD) | 1.5 (1.18) | 1.73 (3.28) | 2.25 (3.35) | 1.3 (0.5) |
| Total LOS Avg.(SD) | 1.58 (1.56) | 1.17 (2.94) | 2.47 (3.68) | 0.94 (0.85) |
| Antivenom ADR (%)* | 26 (19.4) | 0 (0) | 20 (17.86) | 0 (0) |
| Outcome code %* | ||||
| No Effect | 4.76 | 29.29 | 0 | 0 |
| Minor | 71.43 | 56.57 | 34.23 | 63.64 |
| Moderate | 20.63 | 13.13 | 54.05 | 36.36 |
| Major | 3.17 | 1.01 | 11.71 | 0 |
Adverse reactions associated with North American Coral Snake Antivenin (Equine) administration were documented in 46 (18.25%) cases. The most common adverse reactions were hives, rash and/or welts (12%); itching (9%); shortness of breath (8%); hypotension (2%) and angioedema (1%). Antihistamines were administered to 46 patients, corticosteroids to 40, and epinephrine to 10 cases to treat these adverse reactions.
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Contact Medical Information.9AM-5PM ET Monday to Friday; excluding holidays.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.